Over the years, Minnesota-based company Polaris (NYSE: PII) has become synonymous with Powersports, developing a variety of off-road vehicles, including the popular RZR lineup. The popular Powersports outfit is now teaming up with Zero Motorcycles, a Santa-Cruz based maker of electronic motorcycles and powertrains to electrify its lineup. On Tuesday, the two companies announced a 10-year agreement to work together to produce electrified off-road vehicles and snowmobiles.

Zero will provide the powertrain technology, hardware, and software while Polaris will develop, manufacture, and sell the vehicles. According to Zero Motorcycles CEO Sam Paschel, the companies will co-develop the technologies and vehicle platforms for this new generation of electrified Powersports with the aim of dramatically expanding the electric options currently on the market.

“Our EV expertise and millions of miles real-world, rubber-meets-the-road EV experience, coupled with Polaris’ broad product portfolio, scale, supply chain, and market leadership, makes this a game-changer for every Powersports enthusiast.”

Although Zero is renowned in the electric motorcycle space as the Tesla of motorcycles, Polaris won’t start selling Zero motorcycles at its dealerships. The partnership will initially be focused on electrifying all the products in the Polaris lineup including their market-leading side-by-side four-wheelers as well as snowmobiles. Polaris CEO Scott Wine says that the goal is to develop vehicles that are not only attractive on their own merits, but actually superior to their combustion engine counterparts.

“The vision that I have is that any customer that wants to buy an electric powertrain product in power sports can buy it from us,” he says, admitting that “it’s going to take us a while to get there.” The Powersports outfit has had some experience with electrification before: in 2011, Polaris acquired Global Electric Motorcars (“GEM”), which makes low-speed vehicles like golf-carts and shuttles. The firm has made and sold “over a billion dollars” worth of electric vehicles.

By partnering with Zero, Wine says, Polaris hopes to add new electric vehicles to its core line of off-road and power sports vehicles. “With Zero as a partner over the next decade, we feel like we can take our entire portfolio and also offer an electric powertrain alternative that, in most cases, is a better solution for our customers than the internal combustion engine that it augments.”

Zero’s engineering expertise, as well as its approach to batteries, was the main thing that attracted him to the motorcycle outfit. “Their battery density is better than any automotive company.”

It would be enlightening to hear what entities like Net Element (NASDAQ: NETE) have to say about the likelihood of the Polaris-Zero Motorcycles partnership being a game changer regarding the electrification of two and three wheelers.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

A study that was published in the Nature Biomedical Engineering journal by Rice University bioengineers demonstrated how the researchers created blood vessel networks from 3D-printed sugar templates which they used to keep tightly packed cells alive for a 2-week period.

Ian Kinstlinger, who is the lead author of the study, said that among the biggest obstacles in developing clinically significant tissues was trying to provide enough nutrients and oxygen to all the millions of living cells in a large tissue structure.

He explained that the development of new materials and technologies that mimic vascular networks that occur naturally had significantly helped with the issue, making it easier for the researchers to provide nutrients and oxygen to plenty of cells. This increased the chances of the cells achieving therapeutic function in the long-term.

The study’s coauthor who is also an assistant professor of bioengineering at Rice University, Jordan Miller, used an open source modified laser cutter to 3D print the sugar templates in his lab.

Laser sintering was used to make these complex 3D templates. Laser sintering and extrusion create 3D shapes using 2D layers. He explained that extrusion printing could not be used in some architectures like branched networks, multivascular networks and overhanging structures. Miller started working on the laser sintering methods soon after joining Rice University in 2013.

With selective laser sintering, researchers were afforded much more control in all 3 dimensions which allowed the researchers to access the cells while simultaneously preserving the sugar material’s utility.

Sugar was used to create the blood vessel templates as it can dissolve in water without harming the surrounding cells and it’s also durable when its dry.

Kinstlinger added that the main benefit of using this method was that they could create tissue structures at a faster rate.

After creating these tissues, the research team then conducted hepatocyte experiments collaboratively with Kelly Stevens, who is a bioengineer from the University of Washington. Stevens’ research group focused on the study of these delicate hepatocyte cells, which are very hard to nourish outside a host’s body.

Stevens states that the method Kinstlinger’s group used was incredibly versatile, as it could be utilized in various material cocktails, unlike other bio-printing technologies.

Miller concluded that the team had shown that the generation of large tissue volumes and sustaining the hepatocytes in those tissues for a period of time to evaluate their function was possible. This, he said, was an exciting step forward. Do biomedical companies like DarioHealth Corp. (NASDAQ: DRIO) think that functional synthetic tissues are just a few years away from reality? Only time will tell.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Many countries and their economies alike have been adversely affected by the coronavirus pandemic. Countries like India plan to use this disruption to lead their economy into a rapid industrialization phase. The ace up their sleeve is the mining sector, which will be the main driver to economic recovery in a post-pandemic world.

Usually, a 1% growth in the mining sector leads to an average 1.3% increase in the industrial production growth rate while 10 indirect jobs are created from 1 direct job. According to the 12^th five-year plan of the Planning Commission of India, for every 1% rise in economic growth, the country’s mining sector generates 6 times more employment than the manufacturing sector and 13 times more job opportunities than the agricultural sector. To achieve this, serious interventions are needed in the mining sector.

The National Mineral Policy (“NMP”), which was revised last year, outlines how the Ministry of Mines encourages large scale investments with the newest technologies in prospecting and mining. By relaxing FDI rules (Foreign Direct Investment), the national mineral policy aimed for substantial investments and also developing mineral exportation strategy for the long-term would help establish the mining sector as an independent industry. Incentivizing exploration is also recommended by the NMP as a way to attract private investments.

Recently, the government allowed up to 100% FDI, with a few exceptions and also permitted commercial mining in the coal sector. This is expected to bring in more investments for the mining sector. However, it is important to realize that opening up FDI doesn’t automatically mean that huge investments are going to be flowing in. To improve the investment environment, inefficient clearance procedures and regulatory restrictions have to be addressed. Only then will the ease of doing business increase, leading to an inflow of investments.

The Ministry of Coal is helping to do just that, by developing a Single Window Clearance Mechanism, which is essentially a quicker way for online applications to be processed and approved. This move into the digital network will help make it easier to carry out business in India by allowing assignees of coal mines to secure approvals in a well-timed manner, which will allow mines to begin their operations sooner.

Despite the government’s move to open the mining sector in India under the stimulus reforms that were recently announced, the sector still has a lot unexploited potential which can be harnessed by implementing suggestions that work towards removing regulatory restrictions.

It would be interesting to see what companies like Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) think about the suitability of the measures planned to fully exploit mining in India.

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

• Clinical-stage biotech developer CNS Pharmaceuticals is working to demonstrate the potential effectiveness of its novel drug, Berubicin, in treating aggressive and rare brain cancer glioblastoma multiforme (“GBM”)
• CNS expects to launch Phase II trials of Berubicin later this year or in Q1 of 2021, building on promising results shown in initial trials
• One patient in the Phase I trial has remained cancer-free over the course of 14 years, and 44 percent of the patients who could be evaluated experienced a clinically significant positive response to Berubicin
• CNS’s laser-focused strategy for developing a GBM therapy is also leading the company to prepare, through its sub-licensee partner WPD Pharmaceuticals, for a first-ever Phase I pediatric trial of Berubicin in Poland as well as continuing the development of the company’s second drug candidate, WP1244, which has shown tremendous promise in stopping cancer proliferation in preclinical studies comparing it to chemotherapy drug daunorubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is building its technologically advanced strategy for demonstrating the potential brain tumor-fighting capabilities of its novel drug Berubicin, announcing recently an agreement with medical imaging company Image Analysis Group (“IAG”) to evaluate upcoming clinical phase II patient trial scansin real time.

IAG’s proprietary platform DYNAMIKA is an AI-driven technology developed to aid in the analysis of patient responses during pharmaceutical trial’s, and IAG has extensive experience in partnering with the biotech industry — oncology companies in particular — to provide a centralized reading of critical data, according to a news release about the partnership (https://ibn.fm/7OTsk).

CNS Pharmaceuticals is developing unique treatments for primary and metastatic cancers of the brain and central nervous system, including the company’s lead drug candidate Berubicin, which aims to treat the aggressive brain cancer glioblastoma multiforme (“GBM”) (https://ibn.fm/4r5U3).

“This drug was designed specifically to penetrate the Blood-Brain Barrier and to treat cancers in the brain, which we all know are extremely difficult given that the brain is the most privileged organ in the body,” CNS CEO John Climaco told attendees at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit as part of the company’s investment highlights presentation at the virtual conference Sept. 22 (https://ibn.fm/AzZv6).

During a 2006 Phase I clinical trial, Berubicin “appeared to demonstrate one durable, complete response against GBM,” Climaco said. The specified patient has remained cancer-free as of the last assessment on Feb. 20 of this year. Twenty-seven of the participating patients were able to be evaluated, and 44 percent of them experienced a clinically significant improvement in condition as a result of the trial.

Regarding IAG’s scientific and clinical imaging expertise in the field of GBM and the prowess of the company’s analytical API, Climaco stated, “IAG has an exemplary track record of partnering closely with companies in the biotech space to provide critical analysis of both efficacy and patient response, which we believe will be pivotal in advancing our Berubicin clinical trials.”

IAG CEO Dr. Olga Kubassova stated the platform will not only help CNS analyze Berubicin’s effectiveness and build scientific evidence of its performance but will also help the company efficiently reduce development costs, uncertainties about outcomes and timelines for the product’s advancement.

In addition to the Berubicin trials, CNS and its partner WPD Pharmaceuticals are preparing for a first-ever Phase I Berubicin trial for pediatric patients who have brain cancer. CNS is also developing a second drug candidate, WP1244, shown in preclinical studies to have a DNA-binding agent 500 times more potent than chemotherapy drug daunorubicin in stopping tumor cell expansion.

“We are laser-focused as a company at this point on a critical unmet medical need, and that is the treatment of glioblastoma, which is the most aggressive, common and incurable form of brain cancer,” Climaco told conference attendees. “If you get glioblastoma, the devastating fact is you’re going to die from that disease. After decades without progress in the treatment of this terrible disease, we believe that Berubicin could potentially be a game-changer.”

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

A new study by the Stony Brook University indicates that fructose consumption may actually aggravate an intestinal inflammation into inflammatory bowel disease. The study, which was led by David Montrose of the Stony Brook University Renaissance School of Medicine, was published in the Cellular and Molecular Gastroenterology and Hepatology online journal.

According to the U.S. CDC, roughly three million Americans are diagnosed with Inflammatory Bowel Diseases (“IBD”) each year, which is a one million increase in the number of cases in comparison with cases in the late 90s. The number of IBD cases appears to be increasing globally as well. The consumption of a Western diet, which includes fructose, has been shown to increase the risk of diabetes and obesity. Now, it turns out Inflammatory Bowel Diseases may also be worsened by the consumption of fructose.

Montrose, who is a faculty researcher in the Cancer Center at Stony Brook University as well as an assistant professor in the Pathology department, says that the increase in the number of IBD cases corresponds with the higher fructose consumption levels in the U.S. and other nations.

The research findings indicate a dietary connection between IBD and fructose. This supports the theory that a high fructose consumption will exacerbate the ailment for people with IBD. These results, he adds, are important as they can be used to give guidance on the alternative dietary choices for individuals who have IBD.

Together with his colleagues at the Weill Cornell Medicine, Montrose ran tests using 3 IBD mouse models. They observed that feeding the mice with high fructose amounts aggravated colonic inflammation with changes in their gut bacteria metabolism, type and localization in the colon. Corresponding mechanistic work showed that the microbiota in the gut was linked to the cause of the harmful effect of the high fructose diet.

The study states in its conclusion that the consumption of dietary fructose in excess had an inflammatory effect on the colon, which could be explained by the changes in distribution, composition and metabolic function of the colonic microbiota.

Montrose reveals that the research’s next steps are to learn more about these findings, and explore further. This includes the evaluation of whether the fructose diet grows colitis-associated tumorigenesis. This is extremely important as many people with IBD have an increased risk of developing colon cancer because of the chronic inflammation of their gut for a huge part of their lives. Biotech companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) could use these research findings to develop some life-saving interventions for people with inflammatory bowel disease in the future.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• VistaGen’s product portfolio consists of three novel drug candidates that, together, target multiple anxiety disorders, depression disorders and neurological disorders
• Two of the company’s drug candidates have received an FDA fast track designation, including for the treatment of social anxiety disorder, major depressive disorder and neuropathic pain.
• The global CNS therapeutics market is estimated to reach $130 billion by 2025
• The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year
• VistaGen is committed to developing and commercializing multiple new generation medications that go beyond the standard of care in large markets for treatment of anxiety, depression and other central nervous system (“CNS”) disorders, potentially addressing the unmet needs of millions worldwide
• The company’s efforts are advanced by a skilled management team with decades of experience in biotechnology, pharmaceuticals, CNS drug development and more

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (“CNS”) disorders.

The company is headquartered in South San Francisco, California, the “Birthplace of Biotechnology,” among the largest cluster of biotechnology companies in the world.

New Generation Medications

VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.

PH94B

Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B is a first-in-class neuroactive nasal spray that, administered in microgram doses, binds to chemosensory receptors in the nasal passage that trigger neural circuits responsible for suppressing fear and anxiety caused by stressful social or performance situations.

PH94B is currently being developed as an acute treatment of anxiety in adults with Social Anxiety Disorder (“SAD”). In December 2019, PH94B became the first drug candidate to be granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for development of a treatment for SAD, positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with the anxiety disorder, if planned Phase 3 studies are successful.

A successful Phase 2 program has been completed, and, after achieving consensus with the FDA in mid-2020 that the design of its Phase 3 studies of PH94B in SAD may mirror the design of the highly statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, the company’s preparations for pivotal Phase 3 clinical development of PH94B are underway.

To support Phase 3 development and commercialization of PH94B for anxiety disorders in large anxiety disorder markets in Asia, VistaGen recently entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, a company formed and currently funded by a large global venture capital firm, CBC Group. The company received a $5 million non-dilutive upfront license payment from EverInsight in August 2020. If Phase 3 development is successful, VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million, plus tiered royalties on sales of PH94B in Greater China, South Korea and Southeast Asia. VistaGen retains exclusive rights to develop and commercialize PH94B in all other markets.

VistaGen is also assessing potential Phase 2A clinical development opportunities to evaluate PH94B in a range of other anxiety disorders, including:

• Adjustment Disorder with Anxiety
• Generalized Anxiety Disorder
• Postpartum Anxiety
• Perioperative Anxiety
• Panic Disorder
• PTSD

PH10

PH10 is an investigational fast-acting synthetic neuroactive nasal spray with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (“MDD”).

Upon self-administration, a microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and intranasal esketamine.

In a published exploratory Phase 2A MDD study, PH10 demonstrated rapid-onset and sustained antidepressant effects without the serious psychological side effects and safety concerns of ketamine-based therapy.

Following successfully completed Phase 2A development of PH10 for MDD, the company is currently preparing for a Phase 2B program in MDD.

VistaGen is also assessing the potential for Phase 2A clinical development of PH10 in a range of other depression-related indications, including:

• Postpartum Depression
• Treatment-resistant Depression
• Suicidal Ideation

AV-101

Part of a class of new generation investigational medicine in neurology and neuropsychiatry known as N-methyl-D-aspartate receptor (“NMDAR”) modulators, AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective NMDAR glycine site antagonist. This drug candidate has the potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

VistaGen is currently evaluating AV-101, in combination with FDA-approved probenecid, in a range of neuropsychiatric and neurological indications, with both MDD and Neuropathic Pain already granted Fast Track designation by the FDA. The company is assessing the combination for a potential Phase 1B study to support a potential Phase 2A program in one or more of the following indications:

• Major Depressive Disorder
• Neuropathic Pain
• Levodopa-induced dyskinesia associated with Parkinson’s disease therapy
• Epilepsy
• Suicidal Ideation

CNS Therapeutics Market Outlook

The global CNS therapeutics market is estimated to reach $130 billion by 2025. The market was valued at approximately $82.3 billion in 2017 and is anticipated to grow at a healthy CAGR of more than 5.93% from 2018 to 2025. Even before the onset of the anxiety- and depression-provoking stressors from the COVID-19 pandemic, this growth was expected to be driven by a rise in mental illnesses and increased awareness of psychiatric disorders (https://ibn.fm/TonuU) – all likely to be amplified by the diverse impacts of the pandemic.

The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://ibn.fm/4yY4d).

VistaGen’s mission is to help address the unmet needs of patients suffering from CNS disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders.

Management Team

Shawn K. Singh, J.D. is the Chief Executive Officer and a Director of VistaGen. He has served on the company’s board of directors since 2000. He has nearly 30 years of experience serving in numerous senior management roles across multiple industries, including private and public biotechnology, pharmaceuticals, medical devices, venture capital, contract research and development, and law. Singh has a B.A. with honors from the University of California – Berkley. He has a J.D. degree from the University of Maryland Carey School of Law. He is also a member of the State Bar of California.

1. Ralph Snodgrass, Ph.D., is the Founder, Chief Scientific Officer and Director of the company. Snodgrass has more than 20 years of experience in the biotechnology field as a senior manager. He is recognized as an expert in stem cell biology, with over 28 years of experience using stem cells as biological research tools to promote development and drug discovery. He received a Ph.D. in immunology from the University of Pennsylvania. Snodgrass has published over 50 scientific papers with more than 17 patents and a number of patent applications.

Mark A. Smith, M.D., Ph.D., is VistaGen’s Chief Medical Officer He has over 20 years of pharmaceutical industry experience, primarily with CNS drug development. Smith has been a successful leader in the discovery and development of approximately 20 investigational new drugs. He has been a part of numerous CNS-related clinical trials. Smith received a bachelor’s and Master of Science from Yale University and a Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California – San Diego. He completed his residency in the psychiatry department at Duke University Medical Center.

Jerrold D. Dotson, CPA, is the Vice President, Chief Financial Officer and Secretary of VistaGen. He has over 25 years of experience in senior management positions in finance and administration at both public and private companies. Dotson is a licensed CPA in California and received his B.S. degree (Cum Laude) in business administration with a concentration in accounting from Abilene Christian College.

Mark A. McPartland is the company’s Vice President of Corporate Development and Investor Relations. He has over 20 years of experience in senior management roles in corporate development and investor relations at both public and private companies. McPartland received his Bachelor’s in business administration and marketing from Coastal Carolina University.

For more information, visit the company’s website at www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

A projection of sales shows the recreational cannabis industry in New Jersey reaching between $850 and $950 million annually by 2024. The state, which has a population of almost 9 million people, will be holding a vote for residents to legalize a recreational marijuana market come November. For many, this is a risk they are willing to invest in, with billions of dollars’ worth of business opportunities riding on the outcome of the vote.

If New Jersey residents approve the marijuana market, many leaders expect a similar chain of events to occur inland and along the Eastern Seaboard, which will create an adult-use cannabis region that will be among the largest globally.

The total population of the states that have been in talks about adult-use legalization which include Pennsylvania, New York, Rhode Island and Connecticut, is 37 million, which is more than four times the number of people who reside in New Jersey.

With a recreational cannabis industry already established in Massachusetts and another smaller market set to launch on October 9 in Maine, the president of the CannaBusiness Association, New Jersey, Scott Rudder, predicts that New Jersey is the last hurdle for Pennsylvania, New York and the surrounding states.

A cannabis attorney, Bridget Hill-Zayat, agrees with Rudder, stating that the legalization of a recreational cannabis market in New Jersey will motivate the surrounding states.

Despite the New Jersey proposal lacking some details like the number of business licenses that will be made available, regulations and laws will be added on by cannabis regulators and state legislators after voters pass the initiative.

According to a DKC Analytics poll that was conducted in July, 68% favor the legalization initiative with 26% against it and another 6% polling as unsure. An earlier poll that was carried out in April by the Monmouth University showed that 61% of the respondents were in favor of the legalization.

At the moment, the state has only 12 medical cannabis dispensaries with a few more expected to open in the months to come. Many believe that the medical marijuana dispensaries currently operating will be the first to operate in the adult-use market, as a way to accelerate but also ease the market’s launch by late 2021.

Rudder predicts a level of urgency from legislators to give the authority and for regulators to establish regulations due to the pressure the sector will be under to create economic opportunities and generate tax revenue. This is mainly because of the effect the coronavirus pandemic has had on the state’s economy. These anticipated economic benefits confirm what the marijuana industry, including companies like The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER), has always believed about the immense benefits of having a regulated cannabis market.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

A new study that centered on global coronavirus transmission data discovered that young people and children are about 40% less likely to be infected with COVID-19 as compared to adults when exposed to an individual who has the virus.

The study, which was co-led by researchers from University College London and published in JAMA Pediatrics, added more than 13,900 studies to its May pre-print in order to update their meta-analysis and systematic review. The additional studies were used to understand how susceptible children were to the coronavirus and whether they transmitted the infection to others.

Professor Russell Viner, who is the lead author of the study stated that they their findings showed that children between 12-14 years appeared significantly less likely to contract the coronavirus from other infected individuals. This comes after the study had assessed two times as many coronavirus population screening and contact tracing studies, which provided them with strong data and conclusions.

However, the data on teenagers was less clear, which led the researchers to assume that teens were just as susceptible to the virus as adults. The research findings discovered that susceptibility was an important element in the chain of infection. The findings also supported the notion that children were likely to play a much smaller role in virus transmission and multiplication of cases in the pandemic, although some uncertainty still remains.

The professor added that the new data discovered would provide additional proof that would be important to governments globally, assisting them in their decision-making to keep learning institutions open amid the pandemic.

The researchers screened a total of 13,962 studies which had been published on PubMed and MedRxiv. These studies helped them determine the 32 studies from 21 nations globally that had useful data. In their entirety, the studies included 268,945 adults and 41,640 young people and children. Young people were defined as individuals under the age of 20 in these studies.

The analysis highlights that young people and children, who are under or between the ages of 12 to 14 had a 44% less chance of contracting SARS-CoV-2 from an infected individual in comparison with adult aged above 20.

While the study gives no information concerning the infectiousness of children, it concludes that children would play a very small role in SARS-CoV-2 transmission at a population level seeing as very few children would be infected by the virus for starters. This conclusion is likely to come as good news to biomedical entities like Predictive Oncology (NASDAQ: POAI) since there is one less vulnerable section for society to worry about during this pandemic.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• The company’s current independent pharmacy member base represents over 50% of the United States pharmaceutical market within that vertical
• Actively used in all 50 states with over 11,700 pharmacies in its network, serving around 15 million patients indirectly through these networks of pharmacies

Pharmaceutical supplies and services provider Trxade Group (NASDAQ: MEDS) benefited from an increased exposure to potential investors in September, by attending several virtual investor events and conferences, where it was given the opportunity to present its innovative platform and its advantages for pharmacy members.

The company started the last month of the third fiscal quarter strong by attending the LD 500 Virtual Investor Conference, held September 1-4. During a presentation on September 2, Trxade CEO Suren Ajjarapu focused on the company’s prescription affordability efforts and its commitment to helping pharmacies met their customers’ needs while remaining profitable.

Following the LD Micro event, Trxade attended the 2020 Colliers Institutional Investor Conference on September 10 and the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16. Mr. Ajjarapu was available for one-on-one meetings during both events and hosted a virtual presentation during the Wainwright convention on September 16.

Such investor events can help Trxade further raise the profile of its supply chain trading platform that offers independent pharmacies nationwide access to the best supplier prices for prescription drugs. Currently, the company has an established presence in all 50 states, with over 11,700 pharmacies in its network. The company is indirectly serving around 15 million patients via these independent pharmacies within its network, according to Ajjarapu. Through the trading platform, independent pharmacies can see “up-to-the-minute” supply and pricing for pharmaceutical needs on a cost-efficient basis.

The Trxade Marketplace Platform uses a proprietary database and algorithms to identify pharmaceuticals likely to be in short supply. These are then delivered to independent pharmacies. The pharmacy’s total annual purchase costs can be reduced by up to 7-10%. No membership or transaction fees are required of them and they gain the ability to off-set negative insurance reimbursements.  The safe, secure, and easy web platform instantly connects to thousands of pharmacies with real-time information.

Integra Pharma Solutions is another Trxade division. Providing quality Rx products with significant savings, Integra Pharma Solutions is a pharmaceutical supplier for healthcare organizations of all sizes. Current healthcare markets serviced via Trxade include Government organizations, hospitals, independent pharmacies, and clinics across the nation. Trxade so far has over $800K+ in awards from the US Department of Veterans Affairs, 23K+ SKUs representing hundreds of manufacturers’ products, 60+ supply partners.

The company’s B2C operations are led via Bonum Health, which provides 24/7 access to Board-Certified Providers and Health Assessment Tools at a time when telehealth services are in high demand. Smart technology allows doctors and specialty providers to view vitals through special integrations like FitBit, iHealth, etc. Pending the outcomes of pilot programs, the company expects to make Bonum Health available nationwide.

Providing the sale of products directly to consumers, Trxade’s Community Specialty Pharmacy handles specialized care for patients suffering from chronic conditions. The focus is on rare or difficult to find medicines, including self-injectables, oral, and other supportive therapies.

This business model is proving beneficial for Trxade. At the end of Q2, the company showcased a 244% increase in revenue and a 74% increase in gross profit. Most of the growth can be attributed to an increase in sale and distribution of personal protective equipment (“PPE”) like N95 masks and sanitizing products, in response to the COVID-19 pandemic, through the Integra Pharma unit. When comparing numbers from June 30, 2020, against June 30, 2019, revenue increased from $5.6 million to $12.8million (“TTM”). Gross profits increased from $4.0 million to $6.2 million.

The main drivers of Trxade Group’s growth strategy are to increase the number of independent pharmacies serviced, increase the number of purchases per pharmacy, and increase the average amount of money spent per pharmacy.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Electric vehicles represent the next frontier of vehicular travel. Thanks to powerful battery packs, electric vehicles run on clean energy and produce minimal to zero emissions, making them the perfect vehicle for customers who are conscious of their carbon footprints. For customers who switch from carbon powered vehicles, especially those who’ve used conventional vehicles for years, taking a crash course on EV batteries and charging is crucial.

Unlike traditional vehicles that run on carbon fuel, electric vehicles are powered by rechargeable lithium-ion battery packs. To refuel a carbon fuel-powered vehicle, all you need to do is head to a gas station and fill the gas tank with as much fuel as you want. It’s a little different for electric vehicles, however. As an EV driver, you will have to rely on a network of charging stations and many choose to have a specialized EV charger installed at their home.

The amount of time it takes to charge the vehicle will depend on the size of its battery pack (let’s use a hypothetical EV with a 50kWh battery) as well as how fast the electric current is being delivered. There are three main types of charging speed: slow, rapid, and fast.

Slow charging, as the name suggests, is the slowest type of charging at around 2.3kW to 3 kW. Household sockets fall into this category, and they charge EVs super slow, taking around 22 hours to fill up a 50kWh EV. Clearly, not the best option if you are in a hurry. However, slow charging may conserve battery life as less heat is produced as a byproduct of internal resistance compared to faster charging.

Fast charging is the most commonly used by EV users. A fast charger will release juice at 7kW or 11kW if you’re using a Tesla Destination charger. A 50kWh electric vehicle would take roughly 8 hours to charge up. Considering that most EVs spend this amount of time parked at home overnight or at work during the day, fast charging is considered by many EV drivers to be the most ideal charging speed.

Rapid charging has been getting a lot of attention recently. Typically found at motorway service stations or on main driving routes, rapid chargers can fill your car up within minutes. A 50kW DC fast charger, common around Europe and North America, can get a 50kWh EV to 80% in around 45 minutes. Ultra-rapid chargers, like Tesla’s Supercharging network, can get an EV from 20% power to 89% within 20 minutes.

However, rapid charging has the potential to degrade your battery pack and ultimately reduce its lifespan. It also tends to be more expensive than slow and fast charging. Ultimately, the charging speed you use will depend on your needs and how much you are willing to part with. Undoubtedly, companies like Net Element (NASDAQ: NETE) would gladly work with EV makers to develop payments solutions for battery pack charging facilities.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Up until now, we have only seen scientists linking the brain to a monitor in sci-fi movies where the evil scientist wants to manipulate the subject’s brain or fry it to pudding. This is now a near-reality after a team of neuroscientists and engineers from the St. Petersburg State University in Russia, Technische Universität Dresden in Germany and University of Sheffield in the UK used the power of 3D printing to improve neural implant technology. The study has been published in Nature Biomedical Engineering.

The team was led by Professor Pavel Musienko from St. Petersburg and Professor Ivan Minev, from the Department of Automatic Control and Systems Engineering at the University of Sheffield. The two developed a neural implant prototype that can be utilized in the development of treatments for issues that plague the nervous system.

The neural implant has previously been utilized in the stimulation of spinal cords of animal models suffering from spinal cord injuries. Now they can also be used to create new treatments for humans who suffer from paralysis. The study shows how the implant fits on the brain’s surface, the peripheral muscles and nerves and the spinal cord. This has opened up a slew of possibilities of its implementation in other neurological disorders.

For many researchers in the worlds of technology, science and medicine, linking the brain through the use of a neural interface to a computer is a goal they would like to achieve. Despite the efforts being made to make this a reality, the innovation field is held back by the lengthy development periods and hefty costs that go into building prototypes.

However, the technology shows huge potential in bringing new treatments for injuries that affect the nervous system, all based on a fusion of electronics and biology. The researchers expect the neural implants to sense and issue small electrical impulses to the nervous system and the brain.

Using 3D printing, the team has demonstrated how prototype implants can be made in a cost effective and quicker way, which will accelerate development and research in that area. Additionally, the implants can be modified easily to target a specific problem or area in the nervous system.

Professor Ivan Minev stated that the research which began at Technische Universität, Germany and continued at the University of Sheffield has shown how 3D orienting can be used to create implant prototypes at a cost and speed that had not previously been done while still keeping the standards that are needed to produce a useful tool. The team has also demonstrated how 3D printers can develop implants that can liaise with the nerves and the brain.

Minev adds that in the future, the implant may be modified to fit a clinical need in patients, with it being printed in the OR as the patient is prepared to go under the knife. Industry watchers say such technology could open up immense possibilities for biomed sector players like DarioHealth Corp. (NASDAQ: DRIO).

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.